Novo Nordisk licenses three early-stage obesity programmes from Kallyope

What's the news? Novo Nordisk has licensed three early-stage obesity programmes from the New York biotech Kallyope, as reported by Fierce Biotech on 18 September 2026. A Novo Nordisk spokesperson confirmed the deal is new and separate from the earlier 2024 licence agreement between the two companies. Financial terms and the specific drug targets have not been disclosed.

Why it matters: The three programmes are not incretins — the family of gut hormones that includes GLP-1, the target behind Novo Nordisk's semaglutide — so this is a bet on different biological mechanisms for weight loss rather than another addition to the crowded incretin market. Kallyope focuses on signals between the gut and the brain, an area Novo Nordisk has tracked since its earlier collaboration with the company. Licensing early-stage assets fits Novo Nordisk's strategy of broadening its metabolic pipeline as competition in obesity treatments intensifies.

Read more: Fierce Biotech, 18 September 2026